The aim of this work is to develop a class of injectable biocompatible PBA-based copolymer microgels with tunable glucose-responsive thresholds for potential use in a self-regulated insulin delivery system at low risk of hypoglycemia using a simple and benign synthetic method. The gene discussed is INS; the disease is Hypoglycemia.